3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Neoplasm Metastasis
1
Carcinoma, Squamous Cell
1
Interventions
Cisplatin
144
Radiotherapy
71
Fluorouracil
50
Radiotherapy, Intensity-Modulated
45
Docetaxel
39
Gemcitabine
38
Cetuximab
38
Carboplatin
31
pembrolizumab
25
Capecitabine
22
Drug Therapy
17
toripalimab
14
Paclitaxel
14
camrelizumab
10
Surgical Procedures, Operative
10
Nivolumab
10
Chemoradiotherapy
10
nimotuzumab
9
Radiation
9
Neoadjuvant Therapy
8
Methotrexate
8
Magnetic Resonance Spectroscopy
8
Chemotherapy, Adjuvant
8
nedaplatin
7
Thyrotropin Alfa
7
Platinum
7
tislelizumab
6
spartalizumab
6
Standard of Care
6
Specimen Handling
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
ficlatuzumab
×
Head & Neck
×
Clear all
NCT06064877
2026-04-09
FIERCE-HN
AVEO Pharmaceuticals, Inc.
Phase 3
Recruiting
410 enrolled